106 related articles for article (PubMed ID: 29189489)
1. Utility of whole-body (head-to-toe) PET/CT in the evaluation of melanoma and sarcoma patients.
Webb HR; Latifi HR; Griffeth LK
Nucl Med Commun; 2018 Jan; 39(1):68-73. PubMed ID: 29189489
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Niederkohr RD; Rosenberg J; Shabo G; Quon A
Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
[TBL] [Abstract][Full Text] [Related]
3. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of whole body
Bower N; Morris A; O'Connor J; Sponagle M; Bahr R; Gilbert R; Mohamed A; Bower J
J Med Imaging Radiat Sci; 2024 Jun; 55(2):212-220. PubMed ID: 38403520
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body versus Routine Skull Base to Mid-thigh
Ozdemir S; McCook B; Klassen C
J Clin Imaging Sci; 2020; 10():47. PubMed ID: 32874752
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
7. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
[TBL] [Abstract][Full Text] [Related]
8. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
10. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients.
Swetter SM; Carroll LA; Johnson DL; Segall GM
Ann Surg Oncol; 2002 Aug; 9(7):646-53. PubMed ID: 12167578
[TBL] [Abstract][Full Text] [Related]
12. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
[TBL] [Abstract][Full Text] [Related]
13. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
14. [Impact of whole body magnetic resonance imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT].
Dellestable P; Granel-Brocard F; Rat AC; Olivier P; Régent D; Schmutz JL
Ann Dermatol Venereol; 2011 May; 138(5):377-83. PubMed ID: 21570561
[TBL] [Abstract][Full Text] [Related]
15. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
16. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
Pfannenberg C; Schwenzer N
Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
[TBL] [Abstract][Full Text] [Related]
17. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
18. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
[TBL] [Abstract][Full Text] [Related]
19. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
[TBL] [Abstract][Full Text] [Related]
20. Whole body PET/CT for initial staging of choroidal melanoma.
Finger PT; Kurli M; Reddy S; Tena LB; Pavlick AC
Br J Ophthalmol; 2005 Oct; 89(10):1270-4. PubMed ID: 16170114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
